{
    "root": "65dafe3e-7450-46dd-932f-6fff7e4e58b6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ondansetron",
    "value": "20250325",
    "ingredients": [
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7774"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "ondansetron injection 5-ht 3 receptor antagonist indicated prevention : \u2022 nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy . ( 1.1 ) \u2022 postoperative nausea and/or vomiting . ( 1.2 )",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "prevention nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy ( 2.1 ) : \u2022 dilution ondansetron injection 50 ml 5 % dextrose injection 0.9 % sodium chloride injection required adult pediatric patients . \u2022 adults pediatric patients 6 months age older : recommended 0.15 mg/kg per dose 3 doses ( maximum 16 mg per dose ) , infused intravenously 15 minutes . \u2022 administer first dose 30 minutes start chemotherapy subsequent doses 4 8 hours first dose . prevention postoperative nausea and/or vomiting ( 2.2 ) : \u2022 dilution ondansetron injection required adult pediatric patients . \u2022 full prescribing information recommended instructions adult pediatric patients 1 month age older . patients severe hepatic impairment ( 2.3 ) : \u2022 exceed total daily dose 8 mg .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ondansetron injection , usp , 2 mg/ml , available follows : 2 ml single dose vial packaged 25s ( ndc 0641-6080-25 ) 20 ml multiple dose vial packaged individually ( ndc 0641-6286-01 ) product , including packaging components , made natural rubber latex . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . protect light . report suspected , contact hikma pharmaceuticals usa inc. 1-877-845-0689 , fda 1-800-fda-1088 www.fda.gov/medwatch . product inquiry call 1-877-845-0689 .",
    "adverseReactions": "ondansetron injection contraindicated patients known hypersensitivity ( e.g . , anaphylaxis ) product components . anaphylactic reported patients taking ondansetron [ ( 6.2 ) ] . concomitant apomorphine ondansetron contraindicated based reports profound hypotension loss consciousness apomorphine administered ondansetron .",
    "indications_original": "Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: \u2022\u00a0 \u00a0nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) \u2022\u00a0 \u00a0postoperative nausea and/or vomiting. ( 1.2 )",
    "contraindications_original": "Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy\u00a0( 2.1 ) : \u2022\u00a0 \u00a0Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients. \u2022\u00a0 \u00a0Adults and pediatric patients 6 months of age and older: The recommended dosage is 0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose), infused intravenously over 15 minutes. \u2022\u00a0 \u00a0Administer the first dose 30 minutes before the start of chemotherapy and subsequent doses 4 and 8 hours after the first dose. Prevention of Postoperative Nausea and/or Vomiting\u00a0( 2.2 ) : \u2022\u00a0 \u00a0Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients. \u2022\u00a0 \u00a0See full prescribing information for the recommended dosage and administration instructions for adult and pediatric patients 1 month of age and older. Patients With Severe Hepatic Impairment\u00a0( 2.3 ) : \u2022\u00a0 \u00a0Do not exceed a total daily dose of 8 mg.",
    "warningsAndPrecautions_original": "Ondansetron Injection, USP, 2 mg/mL, is available as follows:\n                  2 mL Single Dose Vial packaged in 25s (NDC 0641-6080-25)\n                  20 mL Multiple Dose Vial packaged individually (NDC 0641-6286-01)\n                  This product, including the packaging components, is not made with natural rubber latex.\n                  \n                     Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [See USP Controlled Room Temperature]. Protect from light.\n                  \n                  To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\n                  For Product Inquiry call 1-877-845-0689.",
    "adverseReactions_original": "Ondansetron Injection is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron\u00a0[see Adverse Reactions (6.2)].\n                  \n                  The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.",
    "drug": [
        {
            "name": "Ondansetron",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7773"
        }
    ]
}